Cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. Our drug candidates include CD101 IV, a long-acting echinocandin antifungal, CD101 topical, and C001, developed using our Cloudbreak™ immunotherapy platform.
Recent News and Insights
Cidara Therapeutics Set to Join Russell Indexes June 23, 2015
Our lead product candidate, CD101 IV, is a novel molecule in the echinocandin class of antifungals. We are initially developing CD101 IV for the treatment of systemic Candida infections. We intend to complete IND-enabling studies and start a Phase I clinical trial in 2015.
We are developing CD101 topical for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). CD101 has demonstrated potent fungicidal activity against Candida species in vitro and has unique physical properties allowing its formulation as a topical agent.
Cloudbreak is a proprietary immunotherapy platform being used to create compounds that direct a patient’s immune cells to attack pathogens that cause infectious disease. Our first candidate, C001, is being developed for the treatment of invasive aspergillosis.
Fungal infections pose significant medical challenges in both the hospital and outpatient settings. These infections typically afflict immunocompromised persons including patients undergoing organ or bone marrow transplantation, chemotherapy, or patients with AIDS.